These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39033046)

  • 1. Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects.
    Choi YS; Hwang JG; Kim JW; Min H; Seong CH; Hong SH; Kim NY; Park MK
    Clin Ther; 2024 Aug; 46(8):622-628. PubMed ID: 39033046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.
    Kim HC; Yang E; Ban MS; Kim YK; Hong SH; Jung J; Jang IJ; Lee S
    Drug Des Devel Ther; 2023; 17():1115-1124. PubMed ID: 37077412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the acid suppression effects between low-dose esomeprazole and famotidine in healthy subjects.
    Kim HY; Hwang JG; Kim JW; Seong CH; Lee JH; Choi YS; Min HJ; Kim HS; Kim HY; Kim YK; Park MK
    Int J Clin Pharmacol Ther; 2023 Sep; 61(9):377-385. PubMed ID: 37382329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed-Release Formulation of Esomeprazole in Healthy Subjects.
    Hwang S; Hong SH; Jung J; Chung JY; Jang IJ; Lee S
    Clin Pharmacol Drug Dev; 2023 Aug; 12(8):839-844. PubMed ID: 36929154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
    Bae S; Kwon J; Lee SB; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2021; 15():5099-5108. PubMed ID: 34992346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the effect of IV administered acid suppressants on gastric pH in dogs.
    Kuhl A; Odunayo A; Price J; Hecht S; Marshall K; Steiner J; Tolbert MK
    J Vet Intern Med; 2020 Mar; 34(2):678-683. PubMed ID: 32020689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
    Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
    Yi S; Lee H; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS
    Aliment Pharmacol Ther; 2017 Aug; 46(3):337-346. PubMed ID: 28543183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
    Morelli G; Chen H; Rossiter G; Rege B; Lu Y
    Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
    Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
    Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of YYD601, a Dual Delayed-Release Formulation of Esomeprazole, Following Single and Multiple Doses in Healthy Adult Volunteers Under Fasting and Fed Conditions.
    Lee HW; Kang WY; Jung W; Gwon MR; Cho K; Yoon YR; Seong SJ
    Drug Des Devel Ther; 2022; 16():619-634. PubMed ID: 35281316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
    Fornai M; Colucci R; Antonioli L; Awwad O; Ugolini C; Tuccori M; Fulceri F; Natale G; Basolo F; Blandizzi C
    Pharmacol Res; 2011 Jan; 63(1):59-67. PubMed ID: 20969958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed-Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects.
    Kim KN; Yang SW; Kim H; Kwak SS; Kim YS; Cho DY
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):53-58. PubMed ID: 28111929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
    Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
    J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
    Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
    Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression.
    Furuta K; Adachi K; Aimi M; Shimura S; Mikami H; Nishimura N; Ishimura N; Ishihara S; Naora K; Kinoshita Y
    Digestion; 2016; 93(2):111-20. PubMed ID: 26637113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB; Allgood LD; Grender JM
    Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.